Researchers Identified New Genetic Target for Fetal Hemoglobin
The BACH2-NRF2 pathway provides a potential new route to boost fetal hemoglobin expression in blood disorders.
Updated on Sept. 30, 2026 in Life Sciences
Live Poll
Should medical research prioritize developing new gene-editing targets alongside existing approved therapies?
Researchers have identified the BACH2-NRF2 axis as a key regulator of fetal hemoglobin expression, operating independently of the known BCL11A pathway. Published in Nature on September 30, 2026, the study provides a new genetic mechanism that could inform future therapies for sickle cell disease and thalassemia.
Why it matters
Identifying alternative therapeutic targets is essential for advancing treatments for hemoglobinopathies, as current approaches often rely on the single BCL11A regulator. By uncovering a parallel pathway, researchers may be able to achieve additive increases in gamma-globin expression.
Analysis of 28,000 individuals revealed that the causal variant rs1010474-C reduces BACH2 expression in erythroid progenitor cells, which typically act as direct repressors of the gamma-globin promoter. Blocking this repressor via base editing or pharmacological inhibition elevates gamma-globin transcription.
The players
Boston Children's Hospital
A pediatric research institution specializing in complex blood disorders and genetic therapies.
Broad Institute
A biomedical research center focused on genomic medicine, CRISPR, and high-throughput data analysis.
The details
The BACH2-NRF2 axis functions as a molecular switch where BACH2 and NRF2 physically interact to regulate transcriptional activity. Researchers used base editors—tools capable of performing precise single-nucleotide substitutions in the genome—to modify the gamma-globin promoter. By combining these edits with short hairpin RNA knockdown, the team confirmed that silencing BACH2 leads to increased expression, a mechanism that remains functional even when the BCL11A pathway is inhibited.
Timeline
December 2023: Casgevy received regulatory approval.
September 30, 2026: Study published in Nature.
The Tech Race
The research advances the field beyond the established BCL11A-targeting Casgevy therapy by identifying an independent regulatory pathway. This discovery marks a departure from reliance on a single transcription regulator and opens a new front in genetic blood disorder treatments.
This development is currently in the research phase and does not yet change clinical treatment for patients with sickle cell disease or thalassemia. Future therapeutic development will depend on verifying the safety and efficacy of BACH2-targeting edits in clinical trials.
The takeaway
The study confirms that targeting the BACH2-NRF2 axis can yield additive increases in gamma-globin expression, offering a potential path to more robust therapeutic outcomes. Watch for future research investigating the clinical safety of simultaneous BCL11A and BACH2 gene editing protocols.
Further reading
For more on emerging genetic research, visit Life Sciences.
Live Poll
Should medical research prioritize developing new gene-editing targets alongside existing approved therapies?
